ArticleFrontiers in immunology2026
Eosinophilic granulomatosis with polyangiitis coexisting with multiple myeloma: independent entities or coexistence? A case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic granulomatosis with polyangiitis (EGPA) represents a systemic necrotizing vasculitis characterized by prominent peripheral eosinophilia. Concomitant plasma cell dyscrasias in the context of EGPA remain exceedingly rare in clinical literature. This paper presents a case of a 49-year-old female patient with recurrent diarrhea, rash, fever, and wheezing. The patient was initially diagnosed with multiple myeloma (MM) due to significant elevation of M protein and immature plasma cells in the bone marrow. However, chemotherapy failed to alleviate her condition, while standardized EGPA treatment achieved disease control. This case of EGPA with clinical manifestations of MM prompts us to consider whether the clinical presentation should follow Occam's razor or Hickam's dictum. Ultimately, we hypothesize that EGPA-induced eosinophil (EOS) perturbs the bone marrow hematopoietic niche. Through the Th2-mediated cytokine milieu, this microenvironment may trigger a reactive, "pseudo-malignant" expansion of plasma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.